Sorafenib pharmaceutical composition and preparation method thereof

By using cross-linked povidone and povidone K30 as carriers and binders in sorafenib tablets, combined with fluidized bed granulation technology, the slow dissolution speed and instability of sorafenib tablets are solved. The problem of this paper achieves high bioavailability and storage stability, reduces the dosage and improves the safety of medication.

CN118948847AInactive Publication Date: 2024-11-15HANGZHOU HUADONG MEDICINE GRP PHARMA RES INST

Patent Information

Application Number
CN202411456985.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-18
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The dissolution rate of sorafenib tablets is slow and unstable, resulting in low bioavailability, stability problems and impurities, affecting the physical characteristics of the drug.

Method used

The solid dispersion of sorafenib is prepared by a fluidized bed granulation coating mechanism using crosslinked povidone as a carrier and combined with povidone K30 as a binder, so as to improve the dissolution speed and stability, and in the composition Pharmaceutically acceptable excipients are added to improve dissolution performance.

Benefits of technology

It significantly improves the dissolution speed and stability of sorafenib, improves bioavailability, reduces the dosage, enhances the safety of medication, and improves storage stability. The process is simple and efficient.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_4
    Figure SMS_4
Patent Text Reader

Abstract

The invention relates to a sorafenib solid dispersion and a preparation method thereof. The solid dispersion comprises sorafenib or a salt thereof, an adhesive and a carrier. The invention further relates to a preparation method of the sorafenib solid dispersion, fluidized bed one-step granulation is adopted, the process is simple, the efficiency is higher, and the industrial application value is high. The invention further relates to a sorafenib composition. The sorafenib composition is high in dissolution speed, high in dissolution stability, high in bioavailability, low in dosage and high in storage stability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceutical preparations, and particularly relates to a pharmaceutical composition containing sorafenib and a preparation method thereof. Background Art

[0002] The chemical name of Sorafenib is: 4-{4-[3-(4-chloro-3-trifluoromethyl-phenyl)-urea]-phenoxy}-pyridine-2-carboxylic acid methylamine;

[0003] Chemical Structure:

[0004] ;

[0005] Molecular formula: C 21 H 16 ClF3N4O3;

[0006] Molecular weight: 465.

[0007] Sorafenib is the first multi-target drug approved for clinical use. It is an oral small molecule multi-kinase inhibitor jointly developed by Bayer and Onyx, and can be used to treat advanced renal cell carcinoma (RCC) and unresectable hepatocellular carcinoma (HCC). Nexavar was first launched in the United States in December 2005 for the treatment of advanced renal cell carcinoma (RCC) and was subsequently launched in France, the United Kingdom and Japan. In October 2007, Nexavar was approved by the European Union for the treatment of hepatocellular carcinoma (HCC), and in November of the same year it was approved by the US FDA, and in 2009 it was approved by Japan. It was approved for marketing in China in 2006 under the trade name Nexavar.

[0008] Sorafenib tosylate is a white to yellow or brown solid that is almost insoluble in water, slightly soluble in methanol and ethanol, and soluble in DMF, DMSO and PEG400.

[0009] According to the biopharmaceutics classification system, sorafenib tosylate is a BCS Class II drug, which is a low-solubility, high-permeability drug. The solubility of sorafenib in aqueous solutions at pH 1.2 to pH 7.4 is very low, which results in a very low dissolution rate of sorafenib tablets in the gastrointestinal tract and becomes the rate-limiting step for absorption. Coupled with the first-pass metabolism, the bioavailability of sorafenib tablets after oral administration is low. Compared with oral solutions, the average relative bioavailability of sorafenib tablets is only 38%-49%. Therefore, the specification of Nexavar is larger, at 200 mg, and two tablets are taken each time, twice a day, with a maximum daily dose of 800 mg. It should not be taken with food (it is advisable to take the medicine 1 hour before or 2 hours after eating), and high-fat food can reduce its bioavailability by 29%. According to the Nexavar instructions, healthy volunteers took 100 mg orally 1477% of the administered dose of C-radiolabeled sorafenib was excreted in the feces, and more than 51% of the excreta was unchanged drug, which indicates that the oral bioavailability of sorafenib tablets is low, and more than half of the administered dose of the drug is excreted in the feces due to solubility reasons.

[0010] The process of food being discharged from the stomach into the duodenum is called gastric emptying. The time it takes for the stomach to empty food is affected by the type of food, and generally speaking, it takes 2 to 3 hours to empty. The physical properties and chemical composition of food are different, and the emptying rate is also different. The oral blood concentration and AUC of sorafenib vary greatly among different individuals, indicating that after oral administration, multiple factors in the gastrointestinal tract affect the dissolution rate and dissolution stability of the drug, thereby affecting drug absorption. In order to avoid the influence of factors such as gastric emptying and diet, it is necessary to improve the stability of the drug in the gastrointestinal tract.

[0011] In order to improve the drug dissolution rate of sorafenib, the prior art uses polymer carriers to prepare sorafenib solid dispersions. However, due to the very low solubility of sorafenib, as the dissolution time increases, sorafenib quickly crystallizes and precipitates, resulting in a sharp decrease in solubility, and the final improvement in in vivo bioavailability is not significant. Patent CN 114916221 B (a high bioavailability sorafenib pharmaceutical composition and application) discloses a sorafenib oral solid dispersion solid preparation, which improves the dissolution rate of sorafenib and increases the stability of the solid dispersion by adding a crystal inhibitor, but the effect is still not ideal. Crystallization occurs after 15-60 minutes of in vitro dissolution, and the solubility decreases significantly. The cumulative solubility is basically below 30% at 240 minutes.

[0012] The applicant has found that there is still a stability problem for Sorafenib. Impurities A, D, E, etc. are all known impurities, namely 4-(4-aminophenoxy)-N-methyl-2-pyridinecarboxamide, 4-(2-formamido-4-pyridyloxy)-anilinecarboxylic acid isopropyl ester and 4-chloro-3-trifluoromethylaniline, which are produced in the process or degraded during storage and use. Sorafenib changes its physical properties and exists in the preparation in an amorphous state, which makes it more likely to produce the above impurities. Summary of the invention

[0013] The purpose of the present invention is to solve the technical defects of the prior art sorafenib preparations such as slow dissolution and instability after dissolution, and to provide a sorafenib composition with fast dissolution rate, high dissolution stability, high bioavailability, low dosage, high storage stability and efficient preparation process.

[0014] To achieve the above object, the present invention provides a solid dispersion containing sorafenib, comprising: sorafenib or its salt, a carrier, and a binder; the carrier is selected from cross-linked polyvinylpyrrolidone; the binder is selected from polyvinylpyrrolidone K30; wherein the mass ratio of sorafenib or its salt to cross-linked polyvinylpyrrolidone is 1: 1-3.5.

[0015] As a preferred technical solution, the mass ratio of sorafenib or its salt to cross-linked polyvinylpyrrolidone is 1:2-3.

[0016] As a preferred technical solution, the mass ratio of sorafenib or its salt to povidone K30 is 1:1-3.

[0017] As a preferred technical solution, the mass ratio of sorafenib or its salt to povidone K30 is 1:2.

[0018] The present invention also provides a method for preparing a solid dispersion containing sorafenib, the method comprising:

[0019] 1) Dissolve the prescribed amount of sorafenib or its salt and the adhesive povidone K30 in a suitable solvent to prepare a drug-containing solution.

[0020] 2) Use a fluidized bed granulator to spray the drug-containing solution onto the carrier cross-linked polyvinylpyrrolidone, and remove the solvent in the fluidized bed to obtain a solid dispersion containing sorafenib.

[0021] The suitable solvent can be a common solvent that can dissolve sorafenib, such as a mixed solvent of methanol-dichloromethane in a weight ratio of 1:1-4, preferably 1:3, and the weight ratio between the added solid material and the solvent is 1:5-40, preferably 1:10-20.

[0022] The present invention also provides a pharmaceutical composition containing sorafenib, wherein the composition comprises the above-mentioned solid dispersion containing sorafenib.

[0023] As a preferred technical solution, the composition may further include pharmaceutically acceptable excipients.

[0024] As a preferred technical solution, the pharmaceutically acceptable excipient is selected from one or more of a filler, a disintegrant, a glidant, and a lubricant.

[0025] The filler is selected from one or more of mannitol, pregelatinized starch, lactose, calcium hydrogen phosphate, starch, microcrystalline cellulose, magnesium sulfate, and calcium sulfate; the disintegrant is selected from one or more of corn starch, partially alpha-starch, hydroxypropyl starch, carboxymethyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, and cross-linked polyvinylpyrrolidone; the lubricant is selected from one or more of magnesium stearate, stearic acid, calcium stearate, sodium stearyl fumarate, polyethylene glycol, hydrogenated vegetable oil, sodium lauryl sulfate, talc, and silicon dioxide; the glidant is selected from one or more of silicon dioxide and talc.

[0026] As a preferred technical solution, the composition containing sorafenib comprises the following components by weight:

[0027] 1 part of solid dispersion containing sorafenib,

[0028] Filler 0-1 part,

[0029] Disintegrant 0-0.5 parts,

[0030] Flow aid 0-0.2 parts,

[0031] Lubricant 0-0.2 parts.

[0032] As a preferred technical solution, the composition containing sorafenib can be in the form of tablets, granules, capsules or pills.

[0033] The present invention also provides a pharmaceutical use, including the use of the above-mentioned solid dispersion or composition containing sorafenib in the preparation of a drug for preventing, treating or alleviating liver cancer, renal cell carcinoma, and thyroid cancer.

[0034] Compared with the prior art, the composition containing sorafenib provided by the present invention has high solubility, fast dissolution rate, and greatly improved dissolution stability. Continuous and stable high solubility can effectively improve bioavailability, improve gastrointestinal stability, reduce AUC variation between individuals, reduce dosage, and improve drug safety. The sample prepared by the composition provided by the present invention has low content of related substances, and after the influencing factors are sampled, the increase of related substances is small, and the content and dissolution are basically unaffected. The composition provided by the present invention adopts fluidized bed one-step granulation, which is simple in process, more efficient, and has high industrial application value. DETAILED DESCRIPTION

[0035] The following examples are used to illustrate the present invention but are not intended to limit the scope of the present invention.

[0036] The dosage of active ingredients in all examples is based on sorafenib free base.

[0037] Example 1: Solid dispersion containing sorafenib

[0038] The prescription is shown in Table 1.

[0039] Table 1 Prescription of Example 1

[0040]

[0041] Preparation method:

[0042] The prescribed amount of active drug and two solid materials, povidone K30, were dissolved in a solvent methanol-dichloromethane mixture (methanol:dichloromethane=1:3, the weight ratio of solid material to mixed solvent was 1:10) to prepare a drug-containing solution.

[0043] At an inlet air temperature of 60-70°C, the solution is sprayed onto a powder bed of cross-linked polyvinylpyrrolidone powder using a fluidized bed granulator coater, the solvent is removed in the fluidized bed, and the mixture is dried with circulating air at 50-60°C until the moisture content is less than 3%, thereby obtaining a solid dispersion containing sorafenib.

[0044] Example 2: Solid dispersion containing sorafenib

[0045] The prescription is shown in Table 2.

[0046] Table 2 Prescription of Example 2

[0047]

[0048] Preparation method:

[0049] The prescribed amount of active drug and two solid materials, povidone K30, are dissolved in a solvent methanol-dichloromethane mixture (methanol:dichloromethane=1:3, the weight ratio of solid material to mixed solvent is 1:10) to prepare a drug-containing solution;

[0050] At a temperature of 60-70°C, the solution is sprayed onto a powder bed of a mixed powder of microcrystalline cellulose and cross-linked polyvinylpyrrolidone using a fluidized bed granulator coater, the solvent is removed in the fluidized bed, and the mixture is dried with circulating air at 50-60°C until the moisture content is less than 3%, thereby obtaining a solid dispersion containing sorafenib.

[0051] Example 3: Solid dispersion containing sorafenib

[0052] The prescription is shown in Table 3.

[0053] Table 3 Prescription of Example 3

[0054]

[0055] Preparation method:

[0056] The prescribed amount of active drug and two solid materials, povidone K30, are dissolved in a solvent methanol-dichloromethane mixture (methanol:dichloromethane=1:3, the weight ratio of solid material to mixed solvent is 1:10) to prepare a drug-containing solution;

[0057] The solution is sprayed onto a powder bed of microcrystalline cellulose powder using a fluidized bed granulator at a temperature of 60-70°C, the solvent is removed in the fluidized bed, and the mixture is dried with circulating air at 50-60°C until the moisture content is less than 3%, thereby obtaining a solid dispersion containing sorafenib.

[0058] Example 4-10: Solid dispersion containing sorafenib

[0059] Sorafenib is calculated as 100 mg. Except for the cross-linked polyvinylpyrrolidone as shown in Table 4, other formulation compositions and preparation methods are the same as those in Example 1.

[0060] The prescription is shown in Table 4.

[0061] Table 4 Prescriptions of Examples 4-10

[0062]

[0063] Example 11-21: Tablet containing sorafenib

[0064] The prescription is shown in Table 5.

[0065] Table 5 Prescriptions of Examples 11-21

[0066]

[0067]

[0068] According to the above prescription, the solid dispersions obtained in Examples 1-10 were mixed with the pharmaceutically acceptable auxiliary material components in Table 5 for 8 minutes, and tableted to obtain Examples 11-20 in tablet form.

[0069] The solid dispersion obtained in Example 1 was directly compressed to obtain Example 21 in the form of tablets.

[0070] Example 22: Granules containing sorafenib

[0071] The solid dispersion of Example 1 was sieved through a 40-mesh screen of a granulator and then packaged to prepare granules, thereby obtaining Example 22 in the form of granules.

[0072] Example 23: Capsules containing sorafenib

[0073] The solid dispersion of Example 1 was filled into capsules to obtain Example 23 in the form of capsules.

[0074] Test Example 1: Dissolution test:

[0075] The in vitro dissolution method adopted the second method of Part IV General Rules 0931 of the Chinese Pharmacopoeia 2020 Edition, with 900 mL of pH 6.8 phosphate buffer solution containing 0.1% sodium dodecyl sulfate (SDS) as the dissolution medium, the temperature was 37±0.5°C, the rotation speed was 100 revolutions per minute, and the operation was carried out in accordance with the law. Samples were taken at 10 min, 15 min, 20 min, 30 min, 45 min, 60 min, 2 h and 24 h, and the cumulative dissolution of the preparation at each time point was detected by high performance liquid chromatography. The dissolution results are shown in Table 6.

[0076] Table 6 In vitro dissolution curve results

[0077]

[0078] The above test results show that: using cross-linked polyvinylpyrrolidone as a carrier, within a certain ratio range, can increase the dissolution rate and significantly improve the dissolution stability. The 24h cumulative dissolution rate of Examples 16-23 is more than 80%, far exceeding that of imported tablets.

[0079] At the same time, the above experimental results show that the sorafenib compositions in the form of tablets, granules and capsules can achieve rapid and stable dissolution, and the solid dispersion containing sorafenib is the key to achieving rapid and stable dissolution of the sorafenib composition.

[0080] Test Example 2, related substances:

[0081] The relevant substances were measured under the degradation product item of the import registration standard (JX20150277) and calculated by the external standard method, requiring that each single impurity is less than 0.2% of the labeled amount, and the total amount of degradation products shall not exceed 0.5% of the labeled amount. The samples of Example 11 and Example 12 were placed in an aluminum bag and placed in an environment of 60±2℃ for 10 days and 30 days, and various indicators were tested and compared with the imported tablets (batch number: BXHX3E1). The results are shown in Table 7.

[0082] Table 7 60℃ high temperature test results

[0083]

[0084] The above test results show that: using cross-linked polyvinylpyrrolidone as a carrier, within a certain proportion range, can increase the dissolution rate while significantly improving the dissolution stability, maintaining the dissolution stability for 24 hours, and the content of related substances is low, and the content and solubility are basically unaffected.

[0085] Test Example 3: Stability Test:

[0086] The formulation process of Example 1 was used for industrial-grade amplification, and three batches were made in parallel to conduct accelerated stability tests and compare with the original tablets. Accelerated stability test conditions: temperature 40°C ± 2°C, relative humidity 75% ± 5%. The specific results are shown in Table 8.

[0087] Table 8 Comparison of the accelerated stability of sorafenib homemade tablets and original research samples after 6 months

[0088]

[0089] From the results of Experimental Example 3, it can be seen that after the process is scaled up, the content of related substances in the composition containing sorafenib prepared by the technical solution provided by the present invention is low, the increase is small, the content is stable, and the dissolution rate and stability are basically not affected.

Claims

1. A solid dispersion containing sorafenib, comprising: Sorafenib or its salt, a carrier, and a binder; the carrier is selected from cross-linked polyvinylpyrrolidone; the binder is selected from polyvinylpyrrolidone K30; The mass ratio of sorafenib or its salt to cross-linked polyvinylpyrrolidone is 1:1-3.

5.

2. The solid dispersion containing sorafenib according to claim 1, characterized in that The mass ratio of sorafenib or its salt to cross-linked polyvinylpyrrolidone is 1:2-3.

3. The solid dispersion containing sorafenib according to any one of claims 1 to 2, characterized in that: The mass ratio of sorafenib or its salt to povidone K30 is 1:1-3.

4. The solid dispersion containing sorafenib according to claim 3, characterized in that The mass ratio of sorafenib or its salt to povidone K30 is 1:

2.

5. A method for preparing a solid dispersion containing sorafenib according to any one of claims 1 to 4, comprising: 1) Dissolve the prescribed amount of sorafenib or its salt and the adhesive povidone K30 in a suitable solvent to prepare a drug-containing solution; 2) Use a fluidized bed granulator to spray the drug-containing solution onto the carrier cross-linked polyvinylpyrrolidone, and remove the solvent in the fluidized bed to obtain a solid dispersion containing sorafenib.

6. A composition containing sorafenib, comprising the solid dispersion containing sorafenib according to any one of claims 1 to 4.

7. The composition containing sorafenib according to claim 6, characterized in that The composition may further comprise a pharmaceutically acceptable excipient.

8. The composition containing sorafenib according to claim 7, characterized in that The pharmaceutically acceptable excipients are one or more of fillers, disintegrants, glidants, and lubricants.

9. The composition containing sorafenib according to claim 8, characterized in that The filler is selected from one or more of mannitol, pregelatinized starch, lactose, calcium hydrogen phosphate, starch, microcrystalline cellulose, magnesium sulfate, and calcium sulfate; the disintegrant is selected from one or more of corn starch, partially alpha-starch, hydroxypropyl starch, carboxymethyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, and cross-linked polyvinylpyrrolidone; the lubricant is selected from one or more of magnesium stearate, stearic acid, calcium stearate, sodium stearyl fumarate, polyethylene glycol, hydrogenated vegetable oil, sodium lauryl sulfate, talc, and silicon dioxide; the glidant is selected from one or more of silicon dioxide and talc.

10. The composition containing sorafenib according to any one of claims 6 to 9, characterized in that, by weight, Contains the following components: 1 part of solid dispersion containing sorafenib, Filler 0-1 part, Disintegrant 0-0.5 parts, Flow aid 0-0.2 parts, Lubricant 0-0.2 parts.

11. The composition containing sorafenib according to claim 10, characterized in that The composition is in the form of tablets, granules, capsules or pills.

12. Use of the solid dispersion containing sorafenib according to any one of claims 1 to 4 and the composition containing sorafenib according to any one of claims 6 to 11 in the preparation of a medicament for preventing, treating or alleviating liver cancer, renal cell carcinoma, and thyroid cancer.

Citation Information

Patent Citations

  • Method for improving dissolution rate of insoluble medicine

    CN106551912A

  • Solid dispersoid of poorly soluble drug CVD (carvedilol), preparation method and application

    CN110279662A

  • Sorafenib pharmaceutical composition with high bioavailability and application

    CN114916221A

  • Solid dispersion for improving solubility of insoluble drug and preparation method thereof

    CN115813861A

  • Sorafenib or dorafenib oral preparation with low taking dosage and high drug exposure and application of sorafenib or dorafenib oral preparation

    CN117693333A

Cited By

  • Sorafenib co-amorphous medicine as well as preparation method and application thereof

    CN122344157A